Interim Market Access Lead

Health Policy and Market Access Expert with over 10 years of experience in shaping healthcare policy and engaging with key stakeholders in oncology and rare diseases across Europe

Adept at building advocacy and access strategies under evolving healthcare policies, with expertise in AMNOG, EU HTA, and JCA, ensuring alignment with legislative developments

Experienced in cross-functional policy strategies and stakeholder engagement, with a focus on maximizing patient access and aligning corporate objectives with health system needs

Often supported small companies and was responsible for their policy affairs management

Analysing and evaluating regional activities in the field of oncology

Development and coordination of a therapy area-specific stakeholder strategy

Representation of interests with decision-makers in self-administration, politics and the medical profession

Collaboration in associations

Coordination and implementation of stakeholder projects

Organisation of projects and events

Deriving recommendations for action as well as budget planning and administrative tasks

Advanced policy and payer strategy to align AMR (Antimicrobial Resistance) efforts with legislative frameworks

Engaged in high-level health policy discussions and industry associations

Managed cross-functional access and policy projects for DACH and EU coordination

Monitored decision of the Pharmacovigilance Risk Assessment Committee (PRAC) and derived conclusions for HTA submission strategy

Managed G-BA audits, oral hearings, and payer negotiations, ensuring value-driven and outcome-oriented market access

Led indication expansion for Upadacitinib, optimizing HTA submissions and market integration for new inflammatory disease indications

Assessed international reference pricing risks and reimbursement feasibility for the HR+/HER2+ MBC indication across major European oncology markets

Developed and delivered go/no-go recommendations for European oncology launch, based on comprehensive market and payer analysis

Designed and implemented Early Access Program (EAP) for the oncology indication, integrating market and regulatory feedback for pre-launch access

Developed market access strategies in Germany, France, and the UK, evaluating payer landscapes and reimbursement opportunities

Led HTA submissions, ensuring optimal alignment of clinical data with European market requirements

Provided strategic recommendations for value positioning and access optimization across multiple countries